Generics Global Group of Eight (G8) Industry Guide 2015-2024
Generics Global Group of Eight (G8) Industry Guide 2015-2024
SUMMARY
The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The G8 countries contributed $193,301.1 million in 2019 to the global generics industry, with a compound annual growth rate (CAGR) of 4.8% between 2015 and 2019. The G8 countries are expected to reach a value of $212,985.7 million in 2024, with a CAGR of 2% over the 2019-24 period.
- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $108,922.3 million in 2019. This was followed by Japan and Germany, with a value of $27,448.4 and $24,290.2 million, respectively.
- The US is expected to lead the generics industry in the G8 nations with a value of $118,075.6 million in 2016, followed by Japan and Germany with expected values of $28,477.5 and $28,107.9 million, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
- Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
- What was the size of the G8 generics market by value in 2019?
- What will be the size of the G8 generics market in 2024?
- What factors are affecting the strength of competition in the G8 generics market?
- How has the market performed over the last five years?
- How large is the G8 generics market in relation to its regional counterparts?
1 INTRODUCTION
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 GROUP OF EIGHT (G8) GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 GENERICS IN FRANCE
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 GENERICS IN GERMANY
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 GENERICS IN ITALY
6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
7 GENERICS IN JAPAN
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators
8 GENERICS IN RUSSIA
8.1. Market Overview
8.2. Market Data
8.3. Market Segmentation
8.4. Market outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators
9 GENERICS IN THE UNITED KINGDOM
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators
10 GENERICS IN THE UNITED STATES
10.1. Market Overview
10.2. Market Data
10.3. Market Segmentation
10.4. Market outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators
11 COMPANY PROFILES
11.1. Pfizer Inc.
11.2. Teva Pharmaceutical Industries Limited
11.3. Apotex, Inc.
11.4. Mylan N.V.
11.5. Les Laboratoires Servier
11.6. Sanofi SA
11.7. STADA Arzneimittel AG
11.8. Daiichi Sankyo Co Ltd
11.9. Sawai Pharmaceutical Co Ltd
11.10. Lupin Ltd
11.11. Krka, d. d., Novo mesto
11.12. Abbott Laboratories
12 APPENDIX
12.1. Methodology
12.2. About MarketLine
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 GROUP OF EIGHT (G8) GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 GENERICS IN FRANCE
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 GENERICS IN GERMANY
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 GENERICS IN ITALY
6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
7 GENERICS IN JAPAN
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators
8 GENERICS IN RUSSIA
8.1. Market Overview
8.2. Market Data
8.3. Market Segmentation
8.4. Market outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators
9 GENERICS IN THE UNITED KINGDOM
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators
10 GENERICS IN THE UNITED STATES
10.1. Market Overview
10.2. Market Data
10.3. Market Segmentation
10.4. Market outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators
11 COMPANY PROFILES
11.1. Pfizer Inc.
11.2. Teva Pharmaceutical Industries Limited
11.3. Apotex, Inc.
11.4. Mylan N.V.
11.5. Les Laboratoires Servier
11.6. Sanofi SA
11.7. STADA Arzneimittel AG
11.8. Daiichi Sankyo Co Ltd
11.9. Sawai Pharmaceutical Co Ltd
11.10. Lupin Ltd
11.11. Krka, d. d., Novo mesto
11.12. Abbott Laboratories
12 APPENDIX
12.1. Methodology
12.2. About MarketLine
LIST OF TABLES
Table 1: G8 generics industry, revenue($m), 2015-24
Table 2: G8 generics industry, revenue by country ($m), 2015-19
Table 3: G8 generics industry forecast, revenue by country ($m), 2019-24
Table 4: Canada generics market value: $ million, 2015–19
Table 5: Canada generics market volume: % of total pharma, 2015–19
Table 6: Canada generics market geography segmentation: $ million, 2019
Table 7: Canada generics market value forecast: $ million, 2019–24
Table 8: Canada generics market volume forecast: % of total pharma, 2019–24
Table 9: Canada size of population (million), 2015–19
Table 10: Canada gdp (constant 2005 prices, $ billion), 2015–19
Table 11: Canada gdp (current prices, $ billion), 2015–19
Table 12: Canada inflation, 2015–19
Table 13: Canada consumer price index (absolute), 2015–19
Table 14: Canada exchange rate, 2015–19
Table 15: France generics market value: $ million, 2015–19
Table 16: France generics market volume: % of total pharma, 2015–19
Table 17: France generics market geography segmentation: $ million, 2019
Table 18: France generics market value forecast: $ million, 2019–24
Table 19: France generics market volume forecast: % of total pharma, 2019–24
Table 20: France size of population (million), 2015–19
Table 21: France gdp (constant 2005 prices, $ billion), 2015–19
Table 22: France gdp (current prices, $ billion), 2015–19
Table 23: France inflation, 2015–19
Table 24: France consumer price index (absolute), 2015–19
Table 25: France exchange rate, 2015–19
Table 26: Germany generics market value: $ billion, 2015–19
Table 27: Germany generics market volume: % of total pharma, 2015–19
Table 28: Germany generics market geography segmentation: $ billion, 2019
Table 29: Germany generics market value forecast: $ billion, 2019–24
Table 30: Germany generics market volume forecast: % of total pharma, 2019–24
Table 31: Germany size of population (million), 2015–19
Table 32: Germany gdp (constant 2005 prices, $ billion), 2015–19
Table 33: Germany gdp (current prices, $ billion), 2015–19
Table 34: Germany inflation, 2015–19
Table 35: Germany consumer price index (absolute), 2015–19
Table 36: Germany exchange rate, 2015–19
Table 37: Italy generics market value: $ million, 2015–19
Table 38: Italy generics market volume: % of total pharma, 2015–19
Table 39: Italy generics market geography segmentation: $ million, 2019
Table 40: Italy generics market value forecast: $ million, 2019–24
Table 41: Italy generics market volume forecast: % of total pharma, 2019–24
Table 42: Italy size of population (million), 2015–19
Table 43: Italy gdp (constant 2005 prices, $ billion), 2015–19
Table 44: Italy gdp (current prices, $ billion), 2015–19
Table 45: Italy inflation, 2015–19
Table 46: Italy consumer price index (absolute), 2015–19
Table 47: Italy exchange rate, 2015–19
Table 48: Japan generics market value: $ billion, 2015–19
Table 49: Japan generics market volume: % of total pharma, 2015–19
Table 50: Japan generics market geography segmentation: $ billion, 2019
Table 1: G8 generics industry, revenue($m), 2015-24
Table 2: G8 generics industry, revenue by country ($m), 2015-19
Table 3: G8 generics industry forecast, revenue by country ($m), 2019-24
Table 4: Canada generics market value: $ million, 2015–19
Table 5: Canada generics market volume: % of total pharma, 2015–19
Table 6: Canada generics market geography segmentation: $ million, 2019
Table 7: Canada generics market value forecast: $ million, 2019–24
Table 8: Canada generics market volume forecast: % of total pharma, 2019–24
Table 9: Canada size of population (million), 2015–19
Table 10: Canada gdp (constant 2005 prices, $ billion), 2015–19
Table 11: Canada gdp (current prices, $ billion), 2015–19
Table 12: Canada inflation, 2015–19
Table 13: Canada consumer price index (absolute), 2015–19
Table 14: Canada exchange rate, 2015–19
Table 15: France generics market value: $ million, 2015–19
Table 16: France generics market volume: % of total pharma, 2015–19
Table 17: France generics market geography segmentation: $ million, 2019
Table 18: France generics market value forecast: $ million, 2019–24
Table 19: France generics market volume forecast: % of total pharma, 2019–24
Table 20: France size of population (million), 2015–19
Table 21: France gdp (constant 2005 prices, $ billion), 2015–19
Table 22: France gdp (current prices, $ billion), 2015–19
Table 23: France inflation, 2015–19
Table 24: France consumer price index (absolute), 2015–19
Table 25: France exchange rate, 2015–19
Table 26: Germany generics market value: $ billion, 2015–19
Table 27: Germany generics market volume: % of total pharma, 2015–19
Table 28: Germany generics market geography segmentation: $ billion, 2019
Table 29: Germany generics market value forecast: $ billion, 2019–24
Table 30: Germany generics market volume forecast: % of total pharma, 2019–24
Table 31: Germany size of population (million), 2015–19
Table 32: Germany gdp (constant 2005 prices, $ billion), 2015–19
Table 33: Germany gdp (current prices, $ billion), 2015–19
Table 34: Germany inflation, 2015–19
Table 35: Germany consumer price index (absolute), 2015–19
Table 36: Germany exchange rate, 2015–19
Table 37: Italy generics market value: $ million, 2015–19
Table 38: Italy generics market volume: % of total pharma, 2015–19
Table 39: Italy generics market geography segmentation: $ million, 2019
Table 40: Italy generics market value forecast: $ million, 2019–24
Table 41: Italy generics market volume forecast: % of total pharma, 2019–24
Table 42: Italy size of population (million), 2015–19
Table 43: Italy gdp (constant 2005 prices, $ billion), 2015–19
Table 44: Italy gdp (current prices, $ billion), 2015–19
Table 45: Italy inflation, 2015–19
Table 46: Italy consumer price index (absolute), 2015–19
Table 47: Italy exchange rate, 2015–19
Table 48: Japan generics market value: $ billion, 2015–19
Table 49: Japan generics market volume: % of total pharma, 2015–19
Table 50: Japan generics market geography segmentation: $ billion, 2019
LIST OF FIGURES
Figure 1: G8 generics industry, revenue($m), 2015-2
Figure 2: G8 Generics industry, revenue by country (%), 2019
Figure 3: G8 generics industry, revenue by country ($m), 2015-19
Figure 4: G8 generics industry forecast, revenue by country ($m), 2019-24
Figure 5: Canada generics market value: $ million, 2015–19
Figure 6: Canada generics market volume: % of total pharma, 2015–19
Figure 7: Canada generics market geography segmentation: % share, by value, 2019
Figure 8: Canada generics market value forecast: $ million, 2019–24
Figure 9: Canada generics market volume forecast: % of total pharma, 2019–24
Figure 10: Forces driving competition in the generics market in Canada, 2019
Figure 11: Drivers of buyer power in the generics market in Canada, 2019
Figure 12: Drivers of supplier power in the generics market in Canada, 2019
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2019
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2019
Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2019
Figure 16: France generics market value: $ million, 2015–19
Figure 17: France generics market volume: % of total pharma, 2015–19
Figure 18: France generics market geography segmentation: % share, by value, 2019
Figure 19: France generics market value forecast: $ million, 2019–24
Figure 20: France generics market volume forecast: % of total pharma, 2019–24
Figure 21: Forces driving competition in the generics market in France, 2019
Figure 22: Drivers of buyer power in the generics market in France, 2019
Figure 23: Drivers of supplier power in the generics market in France, 2019
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2019
Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2019
Figure 26: Drivers of degree of rivalry in the generics market in France, 2019
Figure 27: Germany generics market value: $ billion, 2015–19
Figure 28: Germany generics market volume: % of total pharma, 2015–19
Figure 29: Germany generics market geography segmentation: % share, by value, 2019
Figure 30: Germany generics market value forecast: $ billion, 2019–24
Figure 31: Germany generics market volume forecast: % of total pharma, 2019–24
Figure 32: Forces driving competition in the generics market in Germany, 2019
Figure 33: Drivers of buyer power in the generics market in Germany, 2019
Figure 34: Drivers of supplier power in the generics market in Germany, 2019
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2019
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2019
Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2019
Figure 38: Italy generics market value: $ million, 2015–19
Figure 39: Italy generics market volume: % of total pharma, 2015–19
Figure 40: Italy generics market geography segmentation: % share, by value, 2019
Figure 41: Italy generics market value forecast: $ million, 2019–24
Figure 42: Italy generics market volume forecast: % of total pharma, 2019–24
Figure 43: Forces driving competition in the generics market in Italy, 2019
Figure 44: Drivers of buyer power in the generics market in Italy, 2019
Figure 45: Drivers of supplier power in the generics market in Italy, 2019
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2019
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2019
Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2019
Figure 49: Japan generics market value: $ billion, 2015–19
Figure 50: Japan generics market volume: % of total pharma, 2015–19
Figure 1: G8 generics industry, revenue($m), 2015-2
Figure 2: G8 Generics industry, revenue by country (%), 2019
Figure 3: G8 generics industry, revenue by country ($m), 2015-19
Figure 4: G8 generics industry forecast, revenue by country ($m), 2019-24
Figure 5: Canada generics market value: $ million, 2015–19
Figure 6: Canada generics market volume: % of total pharma, 2015–19
Figure 7: Canada generics market geography segmentation: % share, by value, 2019
Figure 8: Canada generics market value forecast: $ million, 2019–24
Figure 9: Canada generics market volume forecast: % of total pharma, 2019–24
Figure 10: Forces driving competition in the generics market in Canada, 2019
Figure 11: Drivers of buyer power in the generics market in Canada, 2019
Figure 12: Drivers of supplier power in the generics market in Canada, 2019
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2019
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2019
Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2019
Figure 16: France generics market value: $ million, 2015–19
Figure 17: France generics market volume: % of total pharma, 2015–19
Figure 18: France generics market geography segmentation: % share, by value, 2019
Figure 19: France generics market value forecast: $ million, 2019–24
Figure 20: France generics market volume forecast: % of total pharma, 2019–24
Figure 21: Forces driving competition in the generics market in France, 2019
Figure 22: Drivers of buyer power in the generics market in France, 2019
Figure 23: Drivers of supplier power in the generics market in France, 2019
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2019
Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2019
Figure 26: Drivers of degree of rivalry in the generics market in France, 2019
Figure 27: Germany generics market value: $ billion, 2015–19
Figure 28: Germany generics market volume: % of total pharma, 2015–19
Figure 29: Germany generics market geography segmentation: % share, by value, 2019
Figure 30: Germany generics market value forecast: $ billion, 2019–24
Figure 31: Germany generics market volume forecast: % of total pharma, 2019–24
Figure 32: Forces driving competition in the generics market in Germany, 2019
Figure 33: Drivers of buyer power in the generics market in Germany, 2019
Figure 34: Drivers of supplier power in the generics market in Germany, 2019
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2019
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2019
Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2019
Figure 38: Italy generics market value: $ million, 2015–19
Figure 39: Italy generics market volume: % of total pharma, 2015–19
Figure 40: Italy generics market geography segmentation: % share, by value, 2019
Figure 41: Italy generics market value forecast: $ million, 2019–24
Figure 42: Italy generics market volume forecast: % of total pharma, 2019–24
Figure 43: Forces driving competition in the generics market in Italy, 2019
Figure 44: Drivers of buyer power in the generics market in Italy, 2019
Figure 45: Drivers of supplier power in the generics market in Italy, 2019
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2019
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2019
Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2019
Figure 49: Japan generics market value: $ billion, 2015–19
Figure 50: Japan generics market volume: % of total pharma, 2015–19
